Wellborn Gayle Furgurson Buys Shares of HealthEquity, Inc.

Wellborn Gayle Furgurson, an insider at HealthEquity, Inc., bought 2,877 shares of the company on June 25, 2026. The transaction occurred as shares traded near $88.58 on Tuesday. This purchase was not made under a pre-planned 10b5-1 trading plan.

Insider Buying and Selling at HealthEquity, Inc.

On June 25, 2026, several insiders, including Wellborn Gayle Furgurson, Gassen William, and Parker Stuart, each bought 2,877 shares of HealthEquity, Inc. None of these transactions were executed under a Rule 10b5-1 plan, indicating they were not pre-planned trades.

HealthEquity, Inc. Stock Down 8.1%

Shares of NasdaqGS:HQY traded near $88.58 on Tuesday. HealthEquity, Inc. boasts a market capitalization of approximately $7.4 billion, with a P/E ratio of 33.1 and a forward P/E of 16.1. The stock's 52-week range spans from $72.76 to $106.60, and it has a 50-day moving average of $85.12 and a 200-day moving average of $88.09. The company maintains a current ratio of 3.44 and a quick ratio of 2.85, with a debt-to-equity ratio of 48.09.

Analysts Set New Price Targets

Analysts have shown confidence in HealthEquity, Inc., with Citizens maintaining a 'buy' rating and a price target of $111 on June 1, 2026. RBC Capital also maintained its 'buy' rating with a $108 target on May 29, 2026, while Barrington Research set a target of $110 on May 22, 2026. The consensus among analysts is a 'buy' recommendation, with a mean target price of $115.56 based on 16 analyst opinions.

About HealthEquity, Inc.

HealthEquity, Inc. is a healthcare company based in Draper, Utah, providing technology-enabled services to consumers and employers across the United States. The firm offers health savings accounts (HSAs), flexible spending accounts (FSAs), and health reimbursement arrangements. Under the leadership of CEO Scott R. Cutler, HealthEquity also provides investment platforms and automated advisory services, serving its clients through a network of brokers, advisors, and health plans.

Bottom Line

Insider purchases like those by Wellborn Gayle Furgurson can be a signal of confidence in HealthEquity, Inc.'s future prospects. The company's strong financial metrics and analyst endorsements further bolster its standing in the market. Investors often track such insider activities as they may provide insights into the company's potential. However, it's important to remember that these insider transactions reflect individual decisions and may not represent the broader market sentiment.